strontium(2+)

• bone mineral density, all sites

  increases

  An increase in BMD was shown at all BMD sites after two to three years in both populations

  PMID:17054253 · one of two readings recorded this

• diarrhoea risk with 2 g strontium ranelate (adverse event)

  increases

  Not recorded as a finding: no node for diarrhoea incidence as an adverse event; diarrhoea-duration node measures time to resolution, a different construct; no estimate stated

  An increased risk of diarrhea with 2 g of strontium ranelate was found; however, adverse events did not affect the risk of discontinuing treatment nor did it increase the risk of serious side effects, gastritis or death.

  PMID:17054253 · one of two readings recorded this

• diarrhoea risk with 2 g strontium ranelate daily, adverse event

  increases

  Not recorded as a finding: No outcome node for diarrhoea incidence; the sentence gives no estimate.

  An increased risk of diarrhea with 2 g of strontium ranelate was found; however, adverse events did not affect the risk of discontinuing treatment nor did it increase the risk of serious side effects, gastritis or death.

  PMID:17054253 · one of two readings recorded this

• discontinuation of treatment due to adverse events

  no effect

  adverse events leading to study withdrawal were not significantly increased with taking 2 g of strontium ranelate daily

  PMID:17054253 · one of two readings recorded this

• non-vertebral fractures

  decreases

  a 14% reduction in non-vertebral fractures (RR 0.86, 95% CI 0.75, 0.98)

  PMID:17054253 · one of two readings recorded this

• vertebral fractures and BMD, dose response

  increases

  Lower doses of strontium ranelate were superior to placebo and the highest dose demonstrated the greatest reduction in vertebral fractures and increase in BMD

  PMID:17054253 · one of two readings recorded this

• vertebral fractures

  decreases

  A 37% reduction in vertebral fractures (RR 0.63, 95% CI 0.56, 0.71)

  PMID:17054253 · one of two readings recorded this

• vertebral fracture incidence

  Incidence (%) | 14.9 | 21.1 | 14.3 | 23.7 | 16.4 | 26.5

  PMID:19436941 · one of two readings recorded this

• vertebral fracture incidence

  Incidence (%) | 14.9 | 21.1 | 14.3 | 23.7 | 16.4 | 26.5

  PMID:19436941 · one of two readings recorded this

• vertebral fracture incidence

  Incidence (%) | 14.9 | 21.1 | 14.3 | 23.7 | 16.4 | 26.5

  PMID:19436941 · one of two readings recorded this

• vertebral fracture incidence

  Incidence (%) | 13.8 | 21.2 | 16.9 | 24.1 | 14.7 | 26.3

  PMID:19436941 · one of two readings recorded this

• vertebral fracture incidence

  Incidence (%) | 13.8 | 21.2 | 16.9 | 24.1 | 14.7 | 26.3

  PMID:19436941 · one of two readings recorded this

• vertebral fracture incidence

  Incidence (%) | 13.8 | 21.2 | 16.9 | 24.1 | 14.7 | 26.3

  PMID:19436941 · one of two readings recorded this

• absolute risk reduction, vertebral fracture

  Absolute risk reduction (%) | 6.2 | 9.4 | 10.2

  PMID:19436941 · one of two readings recorded this

• absolute risk reduction, vertebral fracture

  Absolute risk reduction (%) | 6.2 | 9.4 | 10.2

  PMID:19436941 · one of two readings recorded this

• absolute risk reduction, vertebral fracture

  Absolute risk reduction (%) | 6.2 | 9.4 | 10.2

  PMID:19436941 · one of two readings recorded this

• absolute risk reduction, vertebral fracture

  Absolute risk reduction (%) | 7.4 | 7.2 | 11.6

  PMID:19436941 · one of two readings recorded this

• absolute risk reduction, vertebral fracture

  Absolute risk reduction (%) | 7.4 | 7.2 | 11.6

  PMID:19436941 · one of two readings recorded this

• absolute risk reduction, vertebral fracture

  Absolute risk reduction (%) | 7.4 | 7.2 | 11.6

  PMID:19436941 · one of two readings recorded this

• lumbar BMD change from baseline

  increases

  The increase in lumbar BMD with strontium ranelate, relative to baseline, at 3 years was 12.5%, 14.6% and 16.5% in b-ALP tertile 1, 2 and 3, respectively

  PMID:19436941 · one of two readings recorded this

• lumbar BMD change from baseline

  increases

  The increase in lumbar BMD with strontium ranelate, relative to baseline, at 3 years was 12.5%, 14.6% and 16.5% in b-ALP tertile 1, 2 and 3, respectively

  PMID:19436941 · one of two readings recorded this

• lumbar BMD change from baseline

  increases

  The increase in lumbar BMD with strontium ranelate, relative to baseline, at 3 years was 12.5%, 14.6% and 16.5% in b-ALP tertile 1, 2 and 3, respectively

  PMID:19436941 · one of two readings recorded this

• lumbar BMD change from baseline

  increases

  12.6%, 13.9% and 16.9% in sCTX tertile 1, 2, and 3, respectively

  PMID:19436941 · one of two readings recorded this

• lumbar BMD change from baseline

  increases

  12.6%, 13.9% and 16.9% in sCTX tertile 1, 2, and 3, respectively

  PMID:19436941 · one of two readings recorded this

• lumbar BMD change from baseline

  increases

  12.6%, 13.9% and 16.9% in sCTX tertile 1, 2, and 3, respectively

  PMID:19436941 · one of two readings recorded this

• lumbar spine BMD by DXA (Hologic), percent change from baseline at 3 years, by tertile of baseline bone turnover

  increases

  Not recorded as a finding: The sentence naming the between-group contrast does not name lumbar BMD, and the percent-increase sentence is relative to baseline within the strontium ranelate arm; only tertile-stratified results are given.

  Lumbar BMD increased progressively during the 3-year analysis period in patients treated with strontium ranelate, but remained virtually unchanged in placebo-treated patients.

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture incidence, placebo highest vs lowest tertile

  increases, p = 0.01

  26.5% vs 21.1% in b-ALP tertiles 3 and 1, p = 0.010

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture incidence, placebo highest vs lowest tertile

  increases, p = 0.043

  26.3% vs 21.2% in sCTX tertiles 3 and 1, p = 0.043

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture relative risk, placebo high vs low bone turnover

  increases

  by 32% when considering b-ALP (RR = 1.32, 95% CI [1.06; 1.62])

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture relative risk, placebo high vs low bone turnover

  increases, p = 0.012

  RR = 1.47, 95% CI [1.08; 1.97], p = 0.012

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture relative risk, placebo high vs low bone turnover

  increases

  24% when considering sCTX (RR = 1.24, 95% CI [1.00; 1.54])

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture, SR vs placebo, all patients

  decreases, p = 0.001

  RR = 0.60, 95% CI [0.53–0.70], p < 0.001

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture, SR vs placebo

  decreases, p = 0.001

  the relative risk reduction with strontium ranelate was 49% (RR = 0.51, 95% CI [0.37; 0.70], p <0.001)

  PMID:19436941 · one of two readings recorded this

• new vertebral fracture, SR vs placebo

  decreases, p = 0.023

  RR reduction of 33% compared to placebo (RR = 0.67, 95% CI [0.47; 0.95], p = 0.023

  PMID:19436941 · one of two readings recorded this

• number needed to treat, vertebral fracture

  NNT | 17 | 11 | 10

  PMID:19436941 · one of two readings recorded this

• number needed to treat, vertebral fracture

  NNT | 17 | 11 | 10

  PMID:19436941 · one of two readings recorded this

• number needed to treat, vertebral fracture

  NNT | 17 | 11 | 10

  PMID:19436941 · one of two readings recorded this

• number needed to treat, vertebral fracture

  NNT | 14 | 14 | 9

  PMID:19436941 · one of two readings recorded this

• number needed to treat, vertebral fracture

  NNT | 14 | 14 | 9

  PMID:19436941 · one of two readings recorded this

• number needed to treat, vertebral fracture

  NNT | 14 | 14 | 9

  PMID:19436941 · one of two readings recorded this

• treatment effect heterogeneity across tertiles, new vertebral fracture

  no effect, p = 0.513

  interaction test p = 0.513 for b-ALP tertiles

  PMID:19436941 · one of two readings recorded this

• treatment effect heterogeneity across tertiles, new vertebral fracture

  no effect, p = 0.29

  p = 0.290 for sCTX tertiles

  PMID:19436941 · one of two readings recorded this

• treatment effect heterogeneity across tertiles, new vertebral fracture

  no effect, p = 0.254

  interaction test p = 0.254

  PMID:19436941 · one of two readings recorded this

• vertebral fracture events

  Eventsa | 114 | 155 | 107 | 175 | 115 | 203

  PMID:19436941 · one of two readings recorded this

• vertebral fracture events

  Eventsa | 114 | 155 | 107 | 175 | 115 | 203

  PMID:19436941 · one of two readings recorded this

• vertebral fracture events

  Eventsa | 114 | 155 | 107 | 175 | 115 | 203

  PMID:19436941 · one of two readings recorded this

• vertebral fracture events

  Eventsa | 105 | 153 | 122 | 181 | 103 | 195

  PMID:19436941 · one of two readings recorded this

• vertebral fracture events

  Eventsa | 105 | 153 | 122 | 181 | 103 | 195

  PMID:19436941 · one of two readings recorded this

• vertebral fracture events

  Eventsa | 105 | 153 | 122 | 181 | 103 | 195

  PMID:19436941 · one of two readings recorded this

• vertebral fracture relative risk

  decreases

  Relative risk [95% CI] | 0.69 [0.54; 0.88] | 0.58 [0.46; 0.74] | 0.58 [0.46; 0.73]

  PMID:19436941 · one of two readings recorded this

• vertebral fracture relative risk

  decreases

  Relative risk [95% CI] | 0.69 [0.54; 0.88] | 0.58 [0.46; 0.74] | 0.58 [0.46; 0.73]

  PMID:19436941 · one of two readings recorded this

• vertebral fracture relative risk

  decreases

  Relative risk [95% CI] | 0.69 [0.54; 0.88] | 0.58 [0.46; 0.74] | 0.58 [0.46; 0.73]

  PMID:19436941 · one of two readings recorded this

• vertebral fracture relative risk

  decreases

  Relative risk [95% CI] | 0.63 [0.49; 0.81] | 0.68 [0.54; 0.85] | 0.53 [0.42; 0.67]

  PMID:19436941 · one of two readings recorded this

• vertebral fracture relative risk

  decreases

  Relative risk [95% CI] | 0.63 [0.49; 0.81] | 0.68 [0.54; 0.85] | 0.53 [0.42; 0.67]

  PMID:19436941 · one of two readings recorded this

• vertebral fracture relative risk

  decreases

  Relative risk [95% CI] | 0.63 [0.49; 0.81] | 0.68 [0.54; 0.85] | 0.53 [0.42; 0.67]

  PMID:19436941 · one of two readings recorded this

• vertebral fracture RR reduction within tertiles of baseline b-ALP and sCTX (subgroups)

  decreases

  Not recorded as a finding: subgroup stratum results; whole-population estimate recorded instead

  The magnitudes of the treatment effects were not significantly different between tertiles (interaction test p = 0.513 for b-ALP tertiles, p = 0.290 for sCTX tertiles).

  PMID:19436941 · one of two readings recorded this

• vertebral fracture, SR vs placebo p value

  decreases, p = 0.003

  p value | 0.003 | <0.001 | <0.001

  PMID:19436941 · one of two readings recorded this

• vertebral fracture, SR vs placebo p value

  decreases, p = 0.001

  p value | 0.003 | <0.001 | <0.001

  PMID:19436941 · one of two readings recorded this

• vertebral fracture, SR vs placebo p value

  decreases, p = 0.001

  p value | 0.003 | <0.001 | <0.001

  PMID:19436941 · one of two readings recorded this

• vertebral fracture, SR vs placebo p value

  decreases, p = 0.001

  p value | <0.001 | <0.001 | <0.001

  PMID:19436941 · one of two readings recorded this

• vertebral fracture, SR vs placebo p value

  decreases, p = 0.001

  p value | <0.001 | <0.001 | <0.001

  PMID:19436941 · one of two readings recorded this

• vertebral fracture, SR vs placebo p value

  decreases, p = 0.001

  p value | <0.001 | <0.001 | <0.001

  PMID:19436941 · one of two readings recorded this

• association of femoral neck BMD change with vertebral fracture incidence, years 9 to 10

  p = 0.03

  the change in femoral neck BMD from years 9 to 10 was significantly associated with vertebral fractures incidence during the same period of time (P = 0.03)

  PMID:22124575 · one of two readings recorded this

• compliance with strontium ranelate

  The mean persistence with strontium ranelate in the 10-year population was 117.8 ± 6.1 months (i.e. 9 years and 9 months); the mean compliance was 89.4 ± 12.6%

  PMID:22124575 · one of two readings recorded this

• cumulative incidence of any osteoporotic fracture, years 6 to 10 vs years 0 to 5

  no effect, p = 0.734

  The cumulative incidence of new fracture in the 10-year population in years 6 to 10 was similar to the cumulative incidence in years 0 to 5 (vertebral fracture: 20.6 ± 3.0% versus 18.5 ± 2.6%, respectively, P = 1.00; non-vertebral fracture: 13.7 ± 2.3% versus 12.9 ± 2.2%, P = 0.672; and any osteoporotic fracture: 30.3 ± 3.1% versus 27.5 ± 2.9%, P = 0.734)

  PMID:22124575 · one of two readings recorded this

• cumulative incidence of new non-vertebral fracture, years 6 to 10 vs years 0 to 5

  no effect, p = 0.672

  The cumulative incidence of new fracture in the 10-year population in years 6 to 10 was similar to the cumulative incidence in years 0 to 5 (vertebral fracture: 20.6 ± 3.0% versus 18.5 ± 2.6%, respectively, P = 1.00; non-vertebral fracture: 13.7 ± 2.3% versus 12.9 ± 2.2%, P = 0.672; and any osteoporotic fracture: 30.3 ± 3.1% versus 27.5 ± 2.9%, P = 0.734)

  PMID:22124575 · one of two readings recorded this

• cumulative incidence of new osteoporotic fracture vs FRAX-matched placebo

  decreases, p = 0.012

  Similarly, the 10-year population had significantly lower rates of nonvertebral fracture and new osteoporotic fracture in years 6 to 10 than the FRAX®-matched placebo population over 5 years (nonvertebral fracture: 13.7 ± 2.3% versus 20.2 ± 2.2%, respectively, RRR 38%, P = 0.023; new osteoporotic fracture: 30.3 ± 3.1% versus 39.2 ± 2.5%, RRR 30%, P = 0.012)

  PMID:22124575 · one of two readings recorded this

• cumulative incidence of new vertebral fracture vs FRAX-matched placebo

  decreases, p = 0.016

  The cumulative incidence of new vertebral fractures in the 10-year population in years 6 to 10 was significantly lower than that observed over 5 years in the FRAX®-matched placebo population (20.6 ± 3.0% versus 28.2 ± 2.4%, respectively; relative reduction in risk [RRR] 35%, P = 0.016)

  PMID:22124575 · one of two readings recorded this

• cumulative incidence of new vertebral fracture, years 6 to 10 vs years 0 to 5

  no effect, p = 1

  The cumulative incidence of new fracture in the 10-year population in years 6 to 10 was similar to the cumulative incidence in years 0 to 5 (vertebral fracture: 20.6 ± 3.0% versus 18.5 ± 2.6%, respectively, P = 1.00; non-vertebral fracture: 13.7 ± 2.3% versus 12.9 ± 2.2%, P = 0.672; and any osteoporotic fracture: 30.3 ± 3.1% versus 27.5 ± 2.9%, P = 0.734)

  PMID:22124575 · one of two readings recorded this

• cumulative incidence of nonvertebral fracture vs FRAX-matched placebo

  decreases, p = 0.023

  Similarly, the 10-year population had significantly lower rates of nonvertebral fracture and new osteoporotic fracture in years 6 to 10 than the FRAX®-matched placebo population over 5 years (nonvertebral fracture: 13.7 ± 2.3% versus 20.2 ± 2.2%, respectively, RRR 38%, P = 0.023; new osteoporotic fracture: 30.3 ± 3.1% versus 39.2 ± 2.5%, RRR 30%, P = 0.012)

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD change, years 9 to 10, by new vertebral fracture status

  Women with new vertebral fractures from years 9 to 10 experienced a simultaneous decrease of 2.4 ± 4.7% in femoral neck BMD, compared with an increase of 1.5 ± 8.3% in women without new vertebral fracture

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD mean change, baseline to year 10

  increases, n = 147

  Baseline to year 10 | 147 | 0.060 ± 0.066*** | 10.7 ± 12.1***

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD mean change, years 0-5

  increases, n = 225

  Years 0–5 | 225 | 0.050 ± 0.044*** | 8.8 ± 8.0***

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD mean change, years 6–10

  n = 130

  Years 6–10 | 130 | 0.010 ± 0.056* | 1.8 ± 9.1*

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD mean relative change, baseline to year 10

  increases, n = 147

  Baseline to year 10 | 147 | 0.060 ± 0.066*** | 10.7 ± 12.1***

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD mean relative change, years 0-5

  increases, n = 225

  Years 0–5 | 225 | 0.050 ± 0.044*** | 8.8 ± 8.0***

  PMID:22124575 · one of two readings recorded this

• femoral neck BMD mean relative change, years 6–10

  n = 130

  Years 6–10 | 130 | 0.010 ± 0.056* | 1.8 ± 9.1*

  PMID:22124575 · one of two readings recorded this

• lumbar spine BMD by DXA (Hologic), mean relative change from baseline over 10 years, single arm

  increases, 34.5 ± 20.2% relative change from baseline to year 10

  Not recorded as a finding: Within-arm change from baseline in an open-label single-arm extension; there is no between-arm contrast for BMD.

  Over the 10-year period, lumbar BMD increased continuously with a mean relative change from baseline of 34.5 ± 20.2% (Table 3) in the 10-year population treated with strontium ranelate.

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD mean change, baseline to year 10

  increases, n = 155

  Baseline to year 10 | 155 | 0.253 ± 0.151*** | 34.5 ± 20.2***

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD mean change, years 0-5

  increases, n = 223

  Years 0–5 | 223 | 0.179 ± 0.105*** | 23.9 ± 13.9***

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD mean change, years 6-10

  increases, n = 146

  Years 6-10 | 146 | 0.070 ± 0.115** | 7.9 ± 12.6**

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD mean relative change, baseline to year 10

  increases, n = 155

  Baseline to year 10 | 155 | 0.253 ± 0.151*** | 34.5 ± 20.2***

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD mean relative change, years 0-5

  increases, n = 223

  Years 0–5 | 223 | 0.179 ± 0.105*** | 23.9 ± 13.9***

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD mean relative change, years 6-10

  increases, n = 146

  Years 6-10 | 146 | 0.070 ± 0.115** | 7.9 ± 12.6**

  PMID:22124575 · one of two readings recorded this

• lumbar spine L2-L4 BMD relative change from baseline over 10 years, DXA

  increases, 34.5 ± 20.2% mean relative change from baseline at year 10

  Not recorded as a finding: within-arm change over time with no control arm (lumbar-spine-bmd node; no between-group contrast)

  Over the 10-year period, lumbar BMD increased continuously with a mean relative change from baseline of 34.5 ± 20.2% (Table 3) in the 10-year population treated with strontium ranelate.

  PMID:22124575 · one of two readings recorded this

• new vertebral fracture risk per 1% increase in femoral neck BMD, years 9 to 10

  decreases

  Each 1% increase in femoral neck BMD was associated with a 15% (95% adjusted confidence interval [CI] 2–26%) decrease in risk for new vertebral fracture

  PMID:22124575 · one of two readings recorded this

• new vertebral fracture risk per 1% increase in total hip BMD, years 9 to 10

  no effect, p = 0.16

  The same trend was observed for total hip BMD (7%; 95% CI 3–17%), but did not reach statistical significance (P = 0.16)

  PMID:22124575 · one of two readings recorded this

• persistence with strontium ranelate

  The mean persistence with strontium ranelate in the 10-year population was 117.8 ± 6.1 months (i.e. 9 years and 9 months); the mean compliance was 89.4 ± 12.6%

  PMID:22124575 · one of two readings recorded this

• total hip BMD mean change, baseline to year 10

  increases, n = 147

  Baseline to year 10 | 147 | 0.077 ± 0.084*** | 11.7 ± 13.6***

  PMID:22124575 · one of two readings recorded this

• total hip BMD mean change, years 0-5

  increases, n = 225

  Years 0–5 | 225 | 0.080 ± 0.056*** | 12.1 ± 11.2***

  PMID:22124575 · one of two readings recorded this

• total hip BMD mean change, years 6–10

  n = 130

  Years 6–10 | 130 | 0.000 ± 0.067 | 0.04 ± 8.9

  PMID:22124575 · one of two readings recorded this

• total hip BMD mean relative change, baseline to year 10

  increases, n = 147

  Baseline to year 10 | 147 | 0.077 ± 0.084*** | 11.7 ± 13.6***

  PMID:22124575 · one of two readings recorded this

• total hip BMD mean relative change, years 0-5

  increases, n = 225

  Years 0–5 | 225 | 0.080 ± 0.056*** | 12.1 ± 11.2***

  PMID:22124575 · one of two readings recorded this

• total hip BMD mean relative change, years 6–10

  n = 130

  Years 6–10 | 130 | 0.000 ± 0.067 | 0.04 ± 8.9

  PMID:22124575 · one of two readings recorded this

• largest time-matched mean QTc interval change from baseline versus placebo (individual heart-rate correction, QTcI), automated ECG with manual over-reading, in healthy volunteers given strontium ranelate 4 g/day for 15 days

  no effect

  Not recorded as a finding: this platform holds no node for the endpoint

  The findings of this study demonstrate that the administration of supratherapeutic repeated oral doses of strontium ranelate (4 g day⁻¹ for 15 days) does not lead to a prolongation of the QT/QT(c) interval above the threshold of regulatory concern.

  PMID:22283848 · one of two readings recorded this

• largest time-matched QT(c)I difference versus placebo

  For strontium ranelate (4 g day⁻¹) the largest time-matched difference in QT(c) I compared with placebo was observed at 1 h post dose (mean [90% CI] 7.54 [5.17, 9.90] ms)

  PMID:22283848 · one of two readings recorded this

• largest time-matched QT(c)I difference versus placebo

  increases

  The largest time-matched difference in QT(c) I (individual QT correction for heart rate) between moxifloxacin 400 mg and placebo was observed at 2 h post dose (mean [95% CI] 10.62 [7.90, 13.35] ms)

  PMID:22283848 · one of two readings recorded this

• QT/QT(c) interval prolongation above threshold of regulatory concern

  no effect

  The findings of this study demonstrate that the administration of supratherapeutic repeated oral doses of strontium ranelate (4 g day⁻¹ for 15 days) does not lead to a prolongation of the QT/QT(c) interval above the threshold of regulatory concern

  PMID:22283848 · one of two readings recorded this

• subjects with QT(c) greater than 480 ms

  no effect

  No subject had a QT(c) greater than 480 ms during the study

  PMID:22283848 · one of two readings recorded this

• creatine phosphokinase change from baseline

  creatine phosphokinase, which increased from baseline with treatment (11.7±85.6 and 20.7±104.4 IU/l with 1 and 2 g/day, respectively), but not placebo (−0.4±68.1 IU/l)

  PMID:23117245 · one of two readings recorded this

• global knee pain (VAS) change

  no effect, p = 0.884

  Global knee pain (VAS), (/100 mm) | −22.9 (29.0) | −0.24 (1.64) (−3.45 to 2.97) | 0.884 | −28.5 (28.3) | −3.01 (1.60) (−6.20 to 0.19) | 0.065 | −24.2 (29.2)

  PMID:23117245 · one of two readings recorded this

• global knee pain (VAS) change

  no effect, p = 0.065

  Global knee pain (VAS), (/100 mm) | −22.9 (29.0) | −0.24 (1.64) (−3.45 to 2.97) | 0.884 | −28.5 (28.3) | −3.01 (1.60) (−6.20 to 0.19) | 0.065 | −24.2 (29.2)

  PMID:23117245 · one of two readings recorded this

• joint space width change, 1 g/day vs 2 g/day

  no effect, p = 0.601

  The change in JSW from baseline was significantly different from placebo in both treatment groups at 12, 24 and 36 months, with no difference between the dosages at any time (p=0.601 at 12 months, p=0.149 at 24 months and p=0.311 at 36 months)

  PMID:23117245 · one of two readings recorded this

• joint space width change, 1 g/day vs 2 g/day

  no effect, p = 0.149

  The change in JSW from baseline was significantly different from placebo in both treatment groups at 12, 24 and 36 months, with no difference between the dosages at any time (p=0.601 at 12 months, p=0.149 at 24 months and p=0.311 at 36 months)

  PMID:23117245 · one of two readings recorded this

• joint space width change, 1 g/day vs 2 g/day

  no effect, p = 0.311

  The change in JSW from baseline was significantly different from placebo in both treatment groups at 12, 24 and 36 months, with no difference between the dosages at any time (p=0.601 at 12 months, p=0.149 at 24 months and p=0.311 at 36 months)

  PMID:23117245 · one of two readings recorded this

• joint space width change (medial tibiofemoral compartment)

  increases, p = 0.001

  Joint space width (mm) | −0.23 (0.56) | 0.14 (0.04) (0.05 to 0.23) | <0.001 | −0.27 (0.63) | 0.10 (0.04) (0.02 to 0.19) | 0.018 | −0.37 (0.59)

  PMID:23117245 · one of two readings recorded this

• joint space width change (medial tibiofemoral compartment)

  increases, p = 0.018

  Joint space width (mm) | −0.23 (0.56) | 0.14 (0.04) (0.05 to 0.23) | <0.001 | −0.27 (0.63) | 0.10 (0.04) (0.02 to 0.19) | 0.018 | −0.37 (0.59)

  PMID:23117245 · one of two readings recorded this

• radioclinical progression

  decreases, p = 0.049

  Radioclinical progression† | 32 (8%) | −3.94 (1.98) (−7.83 to −0.05) | 0.049 | 28 (7%) | −5.12 (1.91) (−8.86 to −1.37) | 0.008 | 53 (12%)

  PMID:23117245 · one of two readings recorded this

• radioclinical progression

  decreases, p = 0.008

  Radioclinical progression† | 32 (8%) | −3.94 (1.98) (−7.83 to −0.05) | 0.049 | 28 (7%) | −5.12 (1.91) (−8.86 to −1.37) | 0.008 | 53 (12%)

  PMID:23117245 · one of two readings recorded this

• radiographic joint space narrowing (minimal medial tibiofemoral JSW, mm, computer-assisted) over 3 years, primary endpoint

  decreases

  Not recorded as a finding: radiographic-joint-space-narrowing node requires standardised weight-bearing knee radiographs; the paper states a fixed-flexion posteroanterior view with positioning frame and never says weight-bearing (instrument not stated)

  Treatment with strontium ranelate was associated with significantly attenuated JSN versus placebo, with −0.23±0.56 mm for 1 g/day and −0.27±0.63 mm for 2 g/day from baseline to end (table 2).

  PMID:23117245 · one of two readings recorded this

• radiological progression, joint space narrowing of 0.5 mm or more over 3 years (proportion of progressors)

  decreases

  Not recorded as a finding: Node incident-knee-oa-mjsn-progression defines progression as at least 1 mm in the medial compartment; this paper uses a 0.5 mm threshold, a different definition.

  There were significantly fewer radiological and radioclinical progressors with strontium ranelate 1 and 2 g/day (table 2).

  PMID:23117245 · one of two readings recorded this

• radiological progression (JSN ≥0.5 mm)

  decreases, p = 0.001

  Radiological progression* | 99 (22%) | −10.80 (2.9) (−16.54 to −5.06) | <0.001 | 116 (26%) | −7.50 (3.0) (−13.34 to −1.66) | 0.012 | 156 (33%)

  PMID:23117245 · one of two readings recorded this

• radiological progression (JSN ≥0.5 mm)

  decreases, p = 0.012

  Radiological progression* | 99 (22%) | −10.80 (2.9) (−16.54 to −5.06) | <0.001 | 116 (26%) | −7.50 (3.0) (−13.34 to −1.66) | 0.012 | 156 (33%)

  PMID:23117245 · one of two readings recorded this

• radiological progression (JSN of 0.5 mm or more over 3 years) and radioclinical progression, proportion of progressors

  decreases

  Not recorded as a finding: no node for a 0.5 mm JSN progressor proportion; incident-knee-oa-mjsn-progression requires 1 mm in the medial compartment on weight-bearing films

  There were significantly fewer radiological and radioclinical progressors with strontium ranelate 1 and 2 g/day (table 2).

  PMID:23117245 · one of two readings recorded this

• treatment compliance

  Mean compliance was 93.3±9.3% (ITT population)

  PMID:23117245 · one of two readings recorded this

• urinary CTX-II relative change, ELISA

  decreases, between-group difference significant versus placebo for both doses

  Not recorded as a finding: sentence never names strontium ranelate (agentless 'between-group difference'), so it does not support the claim on its own

  Urinary CTX-II decreased in all groups, and the between-group difference in the relative change was significant for both dosages versus placebo (p=0.003 for 1 g/day and p=0.021 for 2 g/day).

  PMID:23117245 · one of two readings recorded this

• urinary CTX-II relative change

  decreases, p = 0.003

  Urinary CTX-II decreased in all groups, and the between-group difference in the relative change was significant for both dosages versus placebo (p=0.003 for 1 g/day and p=0.021 for 2 g/day)

  PMID:23117245 · one of two readings recorded this

• urinary CTX-II relative change

  decreases, p = 0.021

  Urinary CTX-II decreased in all groups, and the between-group difference in the relative change was significant for both dosages versus placebo (p=0.003 for 1 g/day and p=0.021 for 2 g/day)

  PMID:23117245 · one of two readings recorded this

• WOMAC pain subscore change

  no effect, p = 0.969

  WOMAC pain subscore (/100 mm) | −14.6 (22.6) | 0.1 (1.3) (−2.6 to 2.7) | 0.969 | −19.1 (23.7) | −3.0 (1.3) (−5.6 to −0.3) | 0.028 | −14.7 (23.5)

  PMID:23117245 · one of two readings recorded this

• WOMAC pain subscore change

  decreases, p = 0.028

  WOMAC pain subscore (/100 mm) | −14.6 (22.6) | 0.1 (1.3) (−2.6 to 2.7) | 0.969 | −19.1 (23.7) | −3.0 (1.3) (−5.6 to −0.3) | 0.028 | −14.7 (23.5)

  PMID:23117245 · one of two readings recorded this

• WOMAC pain subscore change

  decreases, p = 0.029

  The reduction in total WOMAC score and pain subscore was numerically greater with treatment than placebo at every visit, with a significant between-group difference for pain subscore at 36 months (p=0.029 for 2 g/day)

  PMID:23117245 · one of two readings recorded this

• WOMAC physical function subscore change

  no effect, p = 0.772

  WOMAC physical function subscore (/100 mm) | −12.2 (21.1) | −0.4 (1.3) (−3.0 to 2.2) | 0.772 | −15.0 (22.2) | −2.2 (1.3) (−4.7 to 0.4) | 0.099 | −11.7 (23.2)

  PMID:23117245 · one of two readings recorded this

• WOMAC physical function subscore change

  no effect, p = 0.099

  WOMAC physical function subscore (/100 mm) | −12.2 (21.1) | −0.4 (1.3) (−3.0 to 2.2) | 0.772 | −15.0 (22.2) | −2.2 (1.3) (−4.7 to 0.4) | 0.099 | −11.7 (23.2)

  PMID:23117245 · one of two readings recorded this

• WOMAC stiffness subscore change

  no effect, p = 0.523

  WOMAC stiffness subscore (/100 mm) | −15.6 (26.9) | −1.0 (1.6) (−4.1 to 2.1) | 0.523 | −18.3 (28.0) | −2.5 (1.6) (−5.6 to 0.6) | 0.120 | −14.0 (29.4)

  PMID:23117245 · one of two readings recorded this

• WOMAC stiffness subscore change

  no effect, p = 0.12

  WOMAC stiffness subscore (/100 mm) | −15.6 (26.9) | −1.0 (1.6) (−4.1 to 2.1) | 0.523 | −18.3 (28.0) | −2.5 (1.6) (−5.6 to 0.6) | 0.120 | −14.0 (29.4)

  PMID:23117245 · one of two readings recorded this

• WOMAC total score, 0 to 300 mm, 2 g/day versus placebo

  decreases, p = 0.045

  Not recorded as a finding: No outcome node for WOMAC total score; only the pain, stiffness and function subscales have nodes.

  Treatment with strontium ranelate 2 g/day was associated with significantly lower WOMAC total score (p=0.045) and pain subscore (p=0.028), and a trend toward lower physical function subscore (p=0.099) and global knee pain (p=0.065) (table 2).

  PMID:23117245 · one of two readings recorded this

• WOMAC total score change

  no effect, p = 0.749

  WOMAC total score (/300 mm) | −41.8 (62.3) | −1.3 (4.0) (−9.0 to 6.5) | 0.749 | −51.9 (66.1) | −8.0 (4.0) (−15.7 to −0.2) | 0.045 | −40.7 (69.1)

  PMID:23117245 · one of two readings recorded this

• WOMAC total score change

  decreases, p = 0.045

  WOMAC total score (/300 mm) | −41.8 (62.3) | −1.3 (4.0) (−9.0 to 6.5) | 0.749 | −51.9 (66.1) | −8.0 (4.0) (−15.7 to −0.2) | 0.045 | −40.7 (69.1)

  PMID:23117245 · one of two readings recorded this

• deaths

  Of 79 randomized patients, 50 (63.3%) died: 24 (60.0%) of 40 patients in the control arm and 26 (66.7%) of 39 patients in the Sr-89 treatment arm

  PMID:25155428 · one of two readings recorded this

• disease progression events

  Of the 79 randomized patients, 56 (70.9%) had disease progression: 28 (70.0%) of 40 patients in the control arm and 28 (71.8%) of 39 patients in the Sr-89 treatment arm

  PMID:25155428 · one of two readings recorded this

• median nadir PSA

  The median nadir PSA levels for patients with ≤6 bone metastases who received and did not receive Sr-89 were 0.1 [range: <0.1–30] and 0.1 [range: <0.1–23.8], respectively, and for those patients with >6 bone metastases, 1.0 [range: <0.1–29] and 0.9 [range: <0.1–87.5], respectively

  PMID:25155428 · one of two readings recorded this

• median overall survival

  Median Ross were 53.5 months (95% CI: 38.0, not attained) in the control arm and 47.4 months (95% CI: 35.9, 87.3) in the treatment arm

  PMID:25155428 · one of two readings recorded this

• median progression-free survival

  Median PFS was 18.5 months (95% CI: [9.7, 49.4]) in the control arm compared with 12.9 months (95% CI: (8.9, 72.5)) in the Sr-89 arm

  PMID:25155428 · one of two readings recorded this

• overall survival, between-arm comparison

  no effect, p = 0.97

  OS did not differ statistically between the arms (= 0.97)

  PMID:25155428 · one of two readings recorded this

• progression-free survival, between-arm comparison

  no effect, p = 0.86

  PFS did not differ statistically between the two arms (= 0.86)

  PMID:25155428 · one of two readings recorded this

• progression-free survival by number of bone metastases (test of equality over strata)

  modulates, p = 0.02

  The test of equality over stratum of EOD showed that it was heterogeneous (p=0.02)

  PMID:25155428 · one of two readings recorded this

• progression-free survival, time from randomization to first disease progression or death, Kaplan-Meier, with one dose of strontium-89 (4 mCi iv) added to androgen deprivation, doxorubicin and zoledronic acid in castrate-sensitive prostate cancer with bone metastases

  no effect, p = 0.86

  Not recorded as a finding: the supporting sentence never names the compound

  PFS did not differ statistically between the two arms (= 0.86).

  PMID:25155428 · one of two readings recorded this

• progression-free survival (time from randomization to first evidence of disease progression or death), Kaplan-Meier; overall survival

  no effect

  Not recorded as a finding: the supporting sentence never names the compound

  PFS did not differ statistically between the two arms (= 0.86).

  PMID:25155428 · one of two readings recorded this

• bone mineral density at the lumbar spine (L1-L4) and proximal femora by DEXA (g/cm2) after 6 months of strontium ranelate 2 g/day

  increases, BMD increases significantly versus baseline and versus control in both strontium ranelate groups

  Not recorded as a finding: the intervention held more than the compound

  Increases in BMD were observed at both the lumbar spine (L1–L4) and proximal femora in both strontium ranelate treatment groups (Table 2; Fig. 1).

  PMID:25480348 · one of two readings recorded this

• collum femoris BMD percent change

  increases

  % Change (↓ ↑) (mean ± SD) | ↑ 0.06 ± 0.02 | ↑ 3.20 ± 0.46 | ↑ 8.17 ± 1.44

  PMID:25480348 · one of two readings recorded this

• collum femoris BMD

  BMD (g/cm2, mean ± SD) | 0.780 ± 0.01 | 0.781 ± 0.01 | 0.780 ± 0.003 | 0.805 ± 0.01 | 0.799 ± 0.02 | 0.862 ± 0.02

  PMID:25480348 · one of two readings recorded this

• equilibrium test time

  Equilibrium test (s, mean ± SD) | 6.49 ± 2.54 | 6.49 ± 2.45 | 6.68 ± 2.95 | 6.69 ± 2.88 | 6.26 ± 2.35 | 8.88 ± 1.50

  PMID:25480348 · one of two readings recorded this

• lumbar spine BMD (L1–L4) percent change

  increases

  % Change (↓ ↑) (mean ± SD) | ↑ 0.24 ± 0.45 | ↑ 4.65 ± 0.56 | ↑ 8.18 ± 0.62

  PMID:25480348 · one of two readings recorded this

• lumbar spine BMD (L1–L4)

  BMD (g/cm2, mean ± SD) | 0.741 ± 0.02 | 0.742 ± 0.01 | 0.746 ± 0.01 | 0.780 ± 0.01 | 0.749 ± 0.01 | 0.810 ± 0.01

  PMID:25480348 · one of two readings recorded this

• lumbar spine (L1-L4) and proximal femur bone mineral density by DEXA (Lunar Prodigy), g/cm2, after 6 months

  increases, BMD increases at lumbar spine and proximal femora in both strontium ranelate groups, significant versus baseline and versus control

  Not recorded as a finding: the intervention held more than the compound

  Increases in BMD were observed at both the lumbar spine (L1–L4) and proximal femora in both strontium ranelate treatment groups (Table 2; Fig. 1).

  PMID:25480348 · one of two readings recorded this

• rising from a chair test time

  Rising from a chair test (s, mean ± SD) | 16.85 ± 2.31 | 16.81 ± 2.36 | 16.61 ± 2.55 | 16.54 ± 2.55 | 16.83 ± 3.12 | 13.86 ± 2.53

  PMID:25480348 · one of two readings recorded this

• serum β-CrossLaps reduction from baseline

  decreases

  Serum levels of β-CrossLaps were reduced compared with baseline in both strontium ranelate groups, by 18.7 % with SrRan and 37.7 % with SrRan + AD3

  PMID:25480348 · one of two readings recorded this

• serum β-CrossLaps reduction from baseline

  decreases

  Serum levels of β-CrossLaps were reduced compared with baseline in both strontium ranelate groups, by 18.7 % with SrRan and 37.7 % with SrRan + AD3

  PMID:25480348 · one of two readings recorded this

• serum β-CrossLaps reduction versus control

  decreases, p = 0.0001

  After 6 months of therapy, this marker of bone resorption was significantly reduced compared with control in patients receiving SrRan (20.3 %, P = 0.03) and SrRan + AD3 (39.4 %, P < 0.0001)

  PMID:25480348 · one of two readings recorded this

• serum β-CrossLaps reduction versus control

  decreases, p = 0.03

  After 6 months of therapy, this marker of bone resorption was significantly reduced compared with control in patients receiving SrRan (20.3 %, P = 0.03) and SrRan + AD3 (39.4 %, P < 0.0001)

  PMID:25480348 · one of two readings recorded this

• serum β-CrossLaps reduction

  decreases, p = 0.008

  A significantly greater reduction was also observed in the SrRan + AD3 group compared with SrRan only (24.0 %; P = 0.008)

  PMID:25480348 · one of two readings recorded this

• serum β-CrossLaps

  β-CrossLaps (ng/ml, mean ± SD) | 0.500 ± 0.16 | 0.482 ± 0.16 | 0.481 ± 0.16 | 0.384 ± 0.11 | 0.472 ± 0.04 | 0.292 ± 0.03

  PMID:25480348 · one of two readings recorded this

• serum PTH reduction

  decreases

  Reductions in mean PTH values were observed in the SrRan, SrRan + AD3 and control groups: 5.8, 9.3 and 2.3 %, respectively

  PMID:25480348 · one of two readings recorded this

• serum PTH reduction

  decreases

  Reductions in mean PTH values were observed in the SrRan, SrRan + AD3 and control groups: 5.8, 9.3 and 2.3 %, respectively

  PMID:25480348 · one of two readings recorded this

• serum PTH reduction

  decreases

  Reductions in mean PTH values were observed in the SrRan, SrRan + AD3 and control groups: 5.8, 9.3 and 2.3 %, respectively

  PMID:25480348 · one of two readings recorded this

• serum PTH

  PTH (pg/ml, mean ± SD) | 68.2 ± 14.5 | 66.7 ± 14.5 | 69.4 ± 7.69 | 65.4 ± 8.35 | 71.1 ± 9.53 | 64.6 ± 9.74

  PMID:25480348 · one of two readings recorded this

• serum TP1NP increase from baseline

  increases, p = 0.001

  Increases in TP1NP, a marker of bone formation, reached statistical significance in women receiving SrRan or a combination of SrRan + AD3 compared with baseline (35.9 %, P < 0.0001, and 51.4 %, P < 0.001, respectively)

  PMID:25480348 · one of two readings recorded this

• serum TP1NP increase from baseline

  increases, p = 0.0001

  Increases in TP1NP, a marker of bone formation, reached statistical significance in women receiving SrRan or a combination of SrRan + AD3 compared with baseline (35.9 %, P < 0.0001, and 51.4 %, P < 0.001, respectively)

  PMID:25480348 · one of two readings recorded this

• serum TP1NP increase versus control

  increases, p = 0.001

  In the SrRan + AD3 group, the increase in TP1NP was also statistically significant compared with control (53.3 %, P < 0.001)

  PMID:25480348 · one of two readings recorded this

• serum TP1NP

  TP1NP (ng/nl, mean ± SD) | 0.294 ± 0.06 | 0.304 ± 0.11 | 0.304 ± 0.07 | 0.414 ± 0.10 | 0.304 ± 0.07 | 0.458 ± 0.11

  PMID:25480348 · one of two readings recorded this

• “up and go” test time, percent reduction

  decreases

  Thus, to perform the “up and go” test before therapy, patients required on average 15.88 ± 0.95 s compared with 13.48 ± 0.82 s after 6 months of therapy, a 14.26 % reduction

  PMID:25480348 · one of two readings recorded this

• “up and go” test time

  “Up and go” test (s, mean ± SD) | 15.26 ± 3.14 | 15.06 ± 3.06 | 15.74 ± 3.45 | 15.69 ± 3.41 | 15.88 ± 3.80 | 13.48 ± 3.28

  PMID:25480348 · one of two readings recorded this

• cartilage volume loss, femur (MRI)

  p = 0.809

  Femur | -7.70 ± 2.66 | -6.98 ± 4.26 | -7.28 ± 2.91 | 0.809*

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, femur (MRI)

  p = 0.02

  Femur | -6.39 ± 3.36 | -5.26 ± 2.92 | 0.020 | -6.16 ± 2.97 | -8.57 ± 2.32 | 0.028

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, femur (MRI)

  p = 0.171

  Femur | -6.15 ± 3.29 | -7.28 ± 2.91 | 0.171

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, global knee (MRI)

  p = 0.351

  Global knee | -7.66 ± 2.10 | -6.67 ± 2.56 | -8.02 ± 3.28 | 0.351*

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, global knee (MRI)

  p = 0.227

  Global knee | -6.75 ± 2.81 | -6.50 ± 2.71 | 0.227 | -6.89 ± 3.70 | -9.33 ± 2.19 | 0.066

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, global knee (MRI)

  p = 0.034

  Global knee | -6.70 ± 2.78 | -8.02 ± 3.28 | 0.034

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, global plateau (MRI)

  decreases, p = 0.017

  Ext+ BML+ patients in the SrRan 1 g/day group demonstrated a significant reduction in cartilage volume loss in the global plateau (P = 0.017) and in the SrRan 2 g/day group in the medial plateau (P = 0.046), compared with placebo

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, lateral plateau

  decreases, p = 0.019

  the Ext+ patients demonstrated that both SrRan 1 g/day and 2 g/day significantly reduced the cartilage volume loss in the lateral plateau (-7.29% ± 3.86, P = 0.019 and -6.46% ± 3.93, P = 0.014, respectively) compared to placebo (-10.90% ± 5.08)

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, lateral plateau

  decreases, p = 0.014

  the Ext+ patients demonstrated that both SrRan 1 g/day and 2 g/day significantly reduced the cartilage volume loss in the lateral plateau (-7.29% ± 3.86, P = 0.019 and -6.46% ± 3.93, P = 0.014, respectively) compared to placebo (-10.90% ± 5.08)

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, lateral plateau

  increases, p = 0.011

  Data further showed that the Ext+ patients also had more cartilage volume loss in the lateral plateau than the Ext- patients (-10.90% ± 5.08 versus -8.57% ± 4.95, P = 0.011)

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial compartment (MRI), multivariate adjusted

  p = 0.12

  In multivariate analysis adjusted as described above, a numerical trend (P = 0.12) toward more cartilage volume loss in the medial compartment in Ext+ patients was found with statistical significance at the medial femur (P = 0.053)

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial compartment (MRI)

  p = 0.119

  Medial compartment | -10.29 ± 3.68 | -9.14 ± 3.27 | -10.40 ± 4.23 | 0.119*

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial compartment (MRI)

  p = 0.09

  Medial compartment | -7.08 ± 4.33 | -9.57 ± 5.29 | 0.090 | -9.69 ± 5.50 | -11.22 ± 1.90 | 0.103

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial compartment (MRI)

  p = 0.0005

  Medial compartment | -7.60 ± 4.63 | -10.40 ± 4.23 | 0.0005

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial femur (MRI), multivariate adjusted

  p = 0.053

  In multivariate analysis adjusted as described above, a numerical trend (P = 0.12) toward more cartilage volume loss in the medial compartment in Ext+ patients was found with statistical significance at the medial femur (P = 0.053)

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial femur (MRI)

  p = 0.29

  Medial femur | -11.17 ± 4.25 | -10.72 ± 5.36 | -10.89 ± 3.19 | 0.290*

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial femur (MRI)

  p = 0.055

  Medial femur | -7.54 ± 4.90 | -9.26 ± 4.03 | 0.055 | -10.72 ± 4.08 | -11.08 ± 1.86 | 0.339

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial femur (MRI)

  p = 0.0002

  Medial femur | -7.90 ± 4.76 | -10.89 ± 3.19 | 0.0002

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial plateau (MRI)

  p = 0.048

  Medial plateau | -8.13 ± 5.98 | -4.90 ± 5.19 | -9.07 ± 8.74 | 0.048* | 0.708** | 0.081**

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial plateau (MRI)

  p = 0.708

  Medial plateau | -8.13 ± 5.98 | -4.90 ± 5.19 | -9.07 ± 8.74 | 0.048* | 0.708** | 0.081**

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial plateau (MRI)

  decreases, p = 0.046

  Ext+ BML+ patients in the SrRan 1 g/day group demonstrated a significant reduction in cartilage volume loss in the global plateau (P = 0.017) and in the SrRan 2 g/day group in the medial plateau (P = 0.046), compared with placebo

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial plateau (MRI)

  p = 0.081

  Medial plateau | -8.13 ± 5.98 | -4.90 ± 5.19 | -9.07 ± 8.74 | 0.048* | 0.708** | 0.081**

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial plateau (MRI)

  p = 0.185

  Medial plateau | -5.79 ± 5.68 | -10.46 ± 11.70 | 0.185 | -7.04 ± 10.97 | -11.45 ± 4.47 | 0.155

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, medial plateau (MRI)

  p = 0.012

  Medial plateau | -6.77 ± 7.52 | -9.07 ± 8.74 | 0.012

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss per additional co-localized factor, femur (MRI)

  p = 0.239

  Femur | -0.53 | 0.239

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss per additional co-localized factor, global knee (MRI)

  p = 0.033

  Global knee | -0.86 | 0.033

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss per additional co-localized factor, medial compartment (MRI)

  p = 0.0005

  Medial compartment | -2.22 | 0.0005

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss per additional co-localized factor, medial femur (MRI)

  p = 0.002

  Medial femur | -1.95 | 0.002

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss per additional co-localized factor, medial plateau (MRI)

  p = 0.006

  Medial plateau | -2.93 | 0.006

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss per additional co-localized factor, plateau (MRI)

  p = 0.007

  Plateau | -1.97 | 0.007

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, plateau (MRI), multivariate adjusted

  decreases, p = 0.014

  SrRan at 2 g/day demonstrated a significant reduction in cartilage volume loss in the global plateau in both univariate (P = 0.007, Table 6) and multivariate analyses (P = 0.014, data not shown)

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, plateau (MRI)

  p = 0.003

  Plateau | -7.61 ± 3.79 | -5.74 ± 3.54 | -10.01 ± 5.79 | 0.003* | 0.070** | 0.007**

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, plateau (MRI)

  p = 0.07

  Plateau | -7.61 ± 3.79 | -5.74 ± 3.54 | -10.01 ± 5.79 | 0.003* | 0.070** | 0.007**

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, plateau (MRI)

  p = 0.007

  Plateau | -7.61 ± 3.79 | -5.74 ± 3.54 | -10.01 ± 5.79 | 0.003* | 0.070** | 0.007**

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, plateau (MRI)

  p = 0.162

  Plateau | -7.38 ± 4.15 | -9.40 ± 7.49 | 0.162 | -8.67 ± 7.12 | -11.57 ± 3.37 | 0.093

  PMID:25888851 · one of two readings recorded this

• cartilage volume loss, plateau (MRI)

  p = 0.005

  Plateau | -7.80 ± 5.05 | -10.01 ± 5.79 | 0.005

  PMID:25888851 · one of two readings recorded this

• joint space width loss, multivariate adjusted

  p = 0.021

  This result was further confirmed in multivariate regression (P = 0.021)

  PMID:25888851 · one of two readings recorded this

• joint space width loss per additional co-localized factor

  p = 0.0001

  % | -11.58 | <0.0001

  PMID:25888851 · one of two readings recorded this

The whole record — 366 rows